HC Wainwright & Co. Reiterates Buy on Calliditas Therapeutics, Maintains $50 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Arthur He reiterates a Buy rating on Calliditas Therapeutics (NASDAQ:CALT) and maintains a $50 price target.
February 22, 2024 | 1:53 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Arthur He reiterates a Buy rating on Calliditas Therapeutics with a $50 price target.
The reiteration of a Buy rating and maintenance of a $50 price target by a reputable analyst firm like HC Wainwright & Co. could instill confidence in investors and potentially lead to a positive short term impact on Calliditas Therapeutics' stock price. Analyst ratings, especially those accompanied by optimistic price targets, can influence market perception and investor sentiment.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100